Active Ingredient(s):Larotrectinib FDA Approved: * November 26, 2018 Pharm Company: *LOXO ONCOLOGY INC Category:Cancer
Larotrectinib, sold under the brand name Vitrakvi, is a medication for the treatment of cancer. It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013.
Larotrectinib was initially awarded orphan drug status in 2015, for soft tissue sarcoma, and breakthrough therapy designation in 2016 for ...
* May have multiple approval dates, manufacturers, or labelers.